Literature DB >> 9681711

The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.

H Buter1, M H Hemmelder, G Navis, P E de Jong, D de Zeeuw.   

Abstract

BACKGROUND: Dietary sodium restriction enhances the antiproteinuric and blood pressure lowering effect of ACE inhibition. In clinical practice, however, long-term compliance to a low-sodium diet may be difficult to obtain. We therefore investigated whether the blunting of the antiproteinuric and blood pressure lowering efficacy of ACE inhibition by high sodium intake can be restored by the addition of a diuretic. PATIENTS AND METHODS: Seven proteinuric patients with non-diabetic renal disease on chronic ACE inhibition were studied during three consecutive 4-week periods: low sodium (50 mmol/day), high sodium (200 mmol/day) and high sodium plus hydrochlorothiazide (50 mg o.i.d.).
RESULTS: During low sodium intake proteinuria was 3.1 (0.7-5.2) g/day, during high sodium intake proteinuria increased to 4.5 (1.6-9.2) g/day (P < 0.05). Interestingly, addition of hydrochlorothiazide again reduced proteinuria to 2.8 (0.6-5.8) g/day (P < 0.05). Mean arterial blood pressure was 89 (84-96), 98 (91-104) and 89 (83-94) mmHg (P < 0.05) during the three periods, respectively.
CONCLUSION: Addition of hydrochlorothiazide can overcome the blunting of the therapeutic efficacy of ACE inhibition on proteinuria and blood pressure by a high sodium intake.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681711     DOI: 10.1093/ndt/13.7.1682

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  39 in total

1.  The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population.

Authors:  Taco B M Monster; Wilbert M T Janssen; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 2.  Treatment of coexisting diabetes and hypertension.

Authors:  N M Kaplan
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

3.  Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease.

Authors:  Enrique Morales; Jara Caro; Eduardo Gutierrez; Angel Sevillano; Pilar Auñón; Cristina Fernandez; Manuel Praga
Journal:  Kidney Int       Date:  2015-08-26       Impact factor: 10.612

Review 4.  Does dietary salt increase the risk for progression of kidney disease?

Authors:  Shiraz I Mishra; Charlotte Jones-Burton; Jeffrey C Fink; Jeanine Brown; George L Bakris; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

5.  Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated.

Authors:  Chadwick E Barnes; William A Wilmer; Raul A Hernandez; Christopher Valentine; Leena S Hiremath; Tibor Nadasdy; Anjali A Satoskar; Rose L Shim; Brad H Rovin; Lee A Hebert
Journal:  Nephron Clin Pract       Date:  2011-07-08

Review 6.  Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.

Authors:  Stuart L Linas
Journal:  Clin J Am Soc Nephrol       Date:  2008-01       Impact factor: 8.237

7.  Should a lower blood pressure goal and albuminuria reduction be mandated to slow hypertensive nephropathy?

Authors:  George L Bakris
Journal:  Curr Hypertens Rep       Date:  2008-10       Impact factor: 5.369

8.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

9.  Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake.

Authors:  Elif I Ekinci; Georgina Thomas; David Thomas; Cameron Johnson; Richard J Macisaac; Christine A Houlihan; Sue Finch; Sianna Panagiotopoulos; Chris O'Callaghan; George Jerums
Journal:  Diabetes Care       Date:  2009-06-23       Impact factor: 17.152

10.  Role of remission clinics in the longitudinal treatment of CKD.

Authors:  Piero Ruggenenti; Elena Perticucci; Paolo Cravedi; Vincenzo Gambara; Marco Costantini; Sanjib Kumar Sharma; Annalisa Perna; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.